PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.76
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
1733.11
Positive sales while TRVN shows negative sales. John Neff would investigate revenue quality advantage.
3.86
Positive equity while TRVN shows negative equity. John Neff would investigate balance sheet advantage.
-18.74
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-18.74
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
3.86
Positive fair value while TRVN shows negative value. John Neff would investigate valuation advantage.
-6.64%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-5.34%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.